Found 214 results
Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E.  2015.  Perimenopause as a neurological transition state.. Nat Rev Endocrinol. 11(7):393-405.
Espeland MA, Brinton RDiaz, Manson JAE, Yaffe K, Hugenschmidt C, Vaughan L, Craft S, Edwards BJ, Casanova R, Masaki K et al..  2015.  Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.. Neurology. 85(13):1131-8.
Frankowski KJ, Slauson SR, Lovell KM, Phillips AM, Streicher JM, Zhou L, Whipple DA, Schoenen FJ, Prisinzano TE, Bohn LM et al..  2015.  Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.. Bioorg Med Chem. 23(14):3948-56.
Lochhead JJ, Wolak DJ, Pizzo ME, Thorne RG.  2015.  Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration.. J Cereb Blood Flow Metab. 35(3):371-81.
Moutal A, François-Moutal L, Perez-Miller S, Cottier K, Chew LAnne, Yeon SKi, Dai J, Park KDuk, Khanna M, Khanna R.  2015.  (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.. Mol Neurobiol.
Kim J-YV, Tillu DV, Quinn TL, Mejia GL, Shy A, Asiedu MNK, Murad E, Schumann AP, Totsch SK, Sorge RE et al..  2015.  Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism.. J Neurosci. 35(16):6307-17.
Caldwell CC, Yao J, Brinton RDiaz.  2015.  Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.. Neurotherapeutics. 12(1):66-80.
Ronaldson PT, Davis TP.  2015.  Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress injury.. Brain Res. 1623:39-52.
Fawley JA, Hofmann ME, Largent-Milnes TM, Andresen MC.  2015.  Temperature differentially facilitates spontaneous but not evoked glutamate release from cranial visceral primary afferents.. PLoS One. 10(5):e0127764.
Slosky LM, Vanderah TW.  2015.  Therapeutic potential of peroxynitrite decomposition catalysts: a patent review.. Expert Opin Ther Pat. :1-24.
Slosky LM, Largent-Milnes TM, Vanderah TW.  2015.  Use of Animal Models in Understanding Cancer-induced Bone Pain.. Cancer Growth Metastasis. 8(Suppl 1):47-62.
Klosinski LP, Yao J, Yin F, Fonteh AN, Harrington MG, Christensen TA, Trushina E, Brinton RDiaz.  2015.  White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.. EBioMedicine. 2(12):1888-904.
Grenald SA, Largent-Milnes TM, Vanderah TW.  2014.  Animal models for opioid addiction drug discovery.. Expert Opin Drug Discov. 9(11):1345-54.
Kumar S, Pan CC, Bloodworth JC, Nixon AB, Theuer C, Hoyt DG, Lee NY.  2014.  Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.. Oncogene. 33(30):3970-9.
Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ.  2014.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.
Hegarty DM, Hermes SM, Largent-Milnes TM, Aicher SA.  2014.  Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.. J Chem Neuroanat. 61-62:1-12.
Moutal A, François-Moutal L, Brittain JM, Khanna M, Khanna R.  2014.  Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides.. Front Cell Neurosci. 8:471.
Wilson SM, Yeon SKi, Yang X-F, Park KDuk, Khanna R.  2014.  Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury.. Front Cell Neurosci. 8:135.
Lee YSun, Muthu D, Hall SM, Ramos-Colon C, Rankin D, Hu J, Sandweiss AJ, De Felice M, Xie JYanhua, Vanderah TW et al..  2014.  Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord.. J Am Chem Soc. 136(18):6608-16.
Thompson BJ, Ronaldson PT.  2014.  Drug delivery to the ischemic brain.. Adv Pharmacol. 71:165-202.
White AG, Watts GS, Lu Z, Meza-Montenegro MM, Lutz EA, Harber P, Burgess JL.  2014.  Environmental arsenic exposure and microbiota in induced sputum.. Int J Environ Res Public Health. 11(2):2299-313.
Rettberg JR, Yao J, Brinton RDiaz.  2014.  Estrogen: a master regulator of bioenergetic systems in the brain and body.. Front Neuroendocrinol. 35(1):8-30.
Hofmann ME, Largent-Milnes TM, Fawley JA, Andresen MC.  2014.  External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.. J Neurophysiol. 112(11):2697-706.
Irwin RW, Solinsky CM, Brinton RDiaz.  2014.  Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.. Front Cell Neurosci. 8:203.
Wilson SM, Moutal A, Melemedjian OK, Wang Y, Ju W, François-Moutal L, Khanna M, Khanna R.  2014.  The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth.. Front Cell Neurosci. 8:196.